Idec/Genentech Rituxan Label May Add Detailed Bulky NHL Data By Year’s End
This article was originally published in Pharmaceutical Approvals Monthly
Idec and Genentech have responded to a Sept. 19 "complete review" letter from FDA for the firms’ Rituxan sBLA to add expanded clinical data to labeling for the non-Hodgkin’s lymphoma (NHL) agent. The companies anticipate approval of the supplement by year’s end.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class